Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
653 Views
eMediNexus 22 December 2017
The US Food and Drug Administration (FDA) has approved Giapreza (angiotensin II) as intravenous infusion to treat dangerously low blood pressure in adults with septic or other distributive shock. Giapreza can cause dangerous blood clots with serious consequences, so, prophylactic treatment for blood clots should be used.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}